|
1
|
Ahmed R, Oborski MJ, Hwang M, Lieberman FS
and Mountz JM: Malignant gliomas: Current perspectives in
diagnosis, treatment, and early response assessment using advanced
quantitative imaging methods. Cancer Manag Res. 6:149–170.
2014.PubMed/NCBI
|
|
2
|
Corwin D, Holdsworth C, Rockne RC, Trister
AD, Mrugala MM, Rockhill JK, Stewart RD, Phillips M and Swanson KR:
Toward patient-specific, biologically optimized radiation therapy
plans for the treatment of glioblastoma. PLoS One. 8:e791152013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanamori M, Higa T, Sonoda Y, Murakami S,
Dodo M, Kitamura H, Taguchi K, Shibata T, Watanabe M, Suzuki H, et
al: Activation of the NRF2 pathway and its impact on the prognosis
of anaplastic glioma patients. Neuro-oncol. 17:555–565. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu B, Emdad L, Bacolod MD, Kegelman TP,
Shen XN, Alzubi MA, Das SK, Sarkar D and Fisher PB: Astrocyte
elevated gene-1 interacts with Akt isoform 2 to control glioma
growth, survival, and pathogenesis. Cancer Res. 74:7321–7332. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Würth R, Pattarozzi A, Gatti M, Bajetto A,
Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, et al:
Metformin selectively affects human glioblastoma tumor-initiating
cell viability: A role for metformin-induced inhibition of Akt.
Cell Cycle. 12:145–156. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto T and Tanigawa N: The role of
survivin as a new target of diagnosis and treatment in human
cancer. Med Electron Microsc. 34:207–212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
8
|
Louis DN, Ohgaki H, Wiestler OD and
Cavenee WK: World Health Organization histological classification
of tumours of the central nervous system. International Agency for
Research on Cancer; Lyon: 2007
|
|
9
|
Altieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ashhab Y, Alian A, Polliack A, Panet A and
Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis
gene with different biological properties and tissue distribution
pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Connor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation of
survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tanaka K, Iwamoto S, Gon G, Nohara T,
Iwamoto M and Tanigawa N: Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer
Res. 6:127–134. 2000.PubMed/NCBI
|
|
14
|
Kleinschmidt-DeMasters BK, Heinz D,
McCarthy PJ, Bobak JB, Lillehei KO, Shroyer AL and Shroyer KR:
Survivin in glioblastomas. Protein and messenger RNA expression and
comparison with telomerase levels. Arch Pathol Lab Med.
127:826–833. 2003.PubMed/NCBI
|
|
15
|
Sasaki T, Lopes MBS, Hankins GR and Helm
GA: Expression of survivin, an inhibitor of apoptosis protein, in
tumors of the nervous system. Acta Neuropathol. 104:105–109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kajiwara Y, Yamasaki F, Hama S, Yahara K,
Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of
survivin in astrocytic tumors: Correlation with malignant grade and
prognosis. Cancer. 97:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chakravarti A, Noll E, Black PM,
Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS:
Quantitatively determined survivin expression levels are of
prognostic value in human gliomas. J Clin Oncol. 20:1063–1068.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y,
Sham JS and Guan XY: Expression of cytoplasmic and nuclear Survivin
in primary and secondary human glioblastoma. Br J Cancer.
94:108–114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanwar RK, Cheung CH, Chang JY and Kanwar
JR: Recent advances in anti-survivin treatments for cancer. Curr
Med Chem. 17:1509–1515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol. 3:279–296. 2011. View Article : Google Scholar
|
|
22
|
Zhang SL, Zhao CQ, Lin B, Li Y and Gao H:
Expression of survivin gene and its relation with the expression of
bcl-2 and bax protein in epithelial ovarian cancer. Zhonghua Fu
Chan Ke Za Zhi. 38:203–206. 2003.(In Chinese). PubMed/NCBI
|
|
23
|
Rödel F, Hoffmann J, Grabenbauer GG,
Papadopoulos T, Weiss C, Günther K, Schick C, Sauer R and Rödel C:
High survivin expression is associated with reduced apoptosis in
rectal cancer and may predict disease-free survival after
preoperative radiochemotherapy and surgical resection. Strahlenther
Onkol. 178:426–435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gradilone A, Gazzaniga P, Ribuffo D,
Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S,
Scuderi N, et al: Survivin, bcl-2, bax, and bcl-X gene expression
in sentinel lymph nodes from melanoma patients. J Clin Oncol.
21:306–312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Connor DS, Schechner JS, Adida C, Mesri
M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC: Control of
apoptosis during angiogenesis by survivin expression in endothelial
cells. Am J Pathol. 156:393–398. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mesri M, Morales-Ruiz M, Ackermann EJ,
Bennett CF, Pober JS, Sessa WC and Altieri DC: Suppression of
vascular endothelial growth factor-mediated endothelial cell
protection by survivin targeting. Am J Pathol. 158:1757–1765. 2001.
View Article : Google Scholar : PubMed/NCBI
|
